First oral neurosteroid treatment for postpartum depression approved
On Aug. 4, 2023, the United States Food and Drug Administration (FDA) approved zuranolone (Zurzuvae) as the first oral neurosteroid treatment for postpartum depression (PPD) in women.
Oct 20, 2023
0
1